Discovery Life Sciences (Discovery) announced that it has entered into an agreement to add the Genomic Services Laboratory (GSL) of the HudsonAlpha Institute for Biotechnology, a gene sequencing and bioinformatics laboratory, to form a new division: HudsonAlpha Discovery. The new division, in combination with Discovery’s current global biospecimen and analytic services, will provide clinically and scientifically annotated biospecimens, gene sequencing, bioinformatics, and lab services to the global pharmaceutical, biotechnology, and diagnostics industries.
This agreement comes on the heels of Discovery’s recent European acquisitions and expansion which cemented the company’s position as the global leader in biospecimen analysis, procurement, processing, and distribution. Genetic sequencing and bioinformatics services are a natural extension of Discovery’s core capabilities. Its new HudsonAlpha Discovery division adds scientists, clinicians, analysts, and bioinformaticians to provide solutions to complex and sophisticated research challenges— through a single provider.
The HudsonAlpha GSL was built at the Institute by genomic scientist, Shawn Levy, PhD, establishing itself as one of the world’s largest academic genomics laboratories. It has supported thousands of research projects and processed hundreds of thousands of biospecimens for healthcare institutions, companies, and investigators around the world. Its scientists provide insights into the understanding of many complex disorders, including cancer, autism, ALS, bipolar disorder, schizophrenia, diabetes, and rare and undiagnosed diseases.
